Radioactive drug plus surgery: new hope for gut tumors?
NCT ID NCT04609592
First seen Sep 30, 2025
Summary
This pilot study tests whether giving a radioactive drug (Lutathera) before and after surgery is safe and feasible for people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug targets tumor cells and delivers radiation directly. Ten participants will receive two doses before surgery, then two more after, to see if this combination can improve outcomes without causing serious complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Cancer Institute Palo Alto
RECRUITINGStanford, California, 95304, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium Lu 177 dotatate (Lutathera) and Gallium 68 Dotatate
What this could lead to
If successful, this approach could improve survival for people with advanced neuroendocrine tumors by combining targeted radiation with surgery.
What could go wrong
This is a very early, small pilot study with only 10 participants. The treatment involves radiation and major surgery, which carry risks like organ damage or surgical complications. It may not prove effective in larger trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.